Generate Biomedicines stock price opens below IPO offering price on the first day

LootboxPhobia · 2026-02-27T20:50:29+00:00

Generate Biomedicines, Inc. is trading at $15 per share today on NASDAQ, below the IPO offering price of $16. The company is advancing clinical trials for the antibody GB-0895 to treat severe asthma and plans to develop other candidate products. Since its founding in 2018, Generate has incurred significant losses, with a net loss of $223 million in 2025.

LootboxPhobia

2026-02-27 20:50:29

Abstract generation in progress

Investing.com - Generate Biomedicines, Inc. (NASDAQ:GENB) began trading today on the Nasdaq Global Select Market at $15 per share, below its $16 initial public offering price. The clinical-stage biopharmaceutical company completed its IPO pricing on Thursday, offering 25 million common shares, with total proceeds of $400 million before underwriting discounts and commissions.

Generate granted underwriters a 30-day option to purchase up to an additional 3.75 million shares at the IPO price (minus underwriting discounts and commissions). The offering is expected to settle on March 2, 2026, subject to customary closing conditions. Goldman Sachs and Morgan Stanley served as joint bookrunners, with Piper Sandler, Guggenheim Securities, and Cantor acting as co-managers.

The company is developing GB-0895, an investigational long-acting monoclonal antibody targeting thymic stromal lymphopoietin, for the treatment of severe asthma, currently recruiting patients in a pivotal Phase 3 trial. The first patient was dosed in one of the Phase 3 studies on January 26, 2026. Generate plans to advance two additional computationally generated oncology candidates into Phase 1 trials by 2026.

Generate’s platform combines generative and predictive models with experimental biological hardware systems to enable scalable validation, including DNA assembly, protein production, and high-throughput screening capabilities. Its cryo-electron microscopy core facility generated over 500 high-resolution maps in 2025. Generate has not yet received regulatory approval for any candidates and has incurred significant operating losses since its founding.

The company reported a net loss of $223 million for the year ending December 31, 2025, compared to a net loss of $181 million in 2024. Collaboration revenue increased from $20.5 million in 2024 to $31.9 million in 2025. Generate was founded by Flagship Pioneering in 2018, and its current CEO is Michael Nally.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes